Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Anson

<< Previous

Bullboard Posts

Next >>

Comment by Azzak34on Nov 14, 2023 3:08pm

144 Views

Post# 35735145

RE:RE:Anson

Great points. We know Pancan is reassessing their program wholesale, we know that because they said that! They're not going to lie on our account. We have an investor who put $15 million in. Our Science is great. Management is questionable, share price is garbage. Oh and the science is great. Stop panicking and drawing conclusions on bits of info.

I reiterate though, management owes some clarity and answers... above and beyond fireside and quarterlies.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China